TY - JOUR

T1 - Risk of hidradenitis suppurativa comorbidities over time

T2 - A prospective cohort study of danish blood donors

AU - Andersen, Rune Kjærsgaard

AU - Loft, Isabella Charlotte

AU - Burgdorf, Kristoffer

AU - Erikstrup, Christian

AU - Pedersen, Ole B.

AU - Jemec, Gregor B.E.

PY - 2021

Y1 - 2021

N2 - Hidradenitis suppurativa is a common recurrent inflammatory skin disease. It is associated with multiple comorbidities whose temporal relationships are unknown due to long diagnostic delays. This study of otherwise healthy blood donors with self-reported symptoms of hidradenitis suppurativa investigated the temporal relationships of comorbidities. A prospective survival analysis on a nationwide cohort of blood donors, using registry data on drug prescription, was used to calculate the hazard ratio of time until first prescription of medical treatment for the following hidradenitis suppurativa-related comorbidities: heart disease, diabetes, depression, thyroid disease and pain. Hidradenitis suppurativa status was determined by a validated questionnaire, and the survival analysis was adjusted for age, sex, body mass index, smoking status and having an International Classification of Diseases Version 10 (ICD-10) diagnosis of hidradenitis suppurativa. Of the participants, 1,012 reported hidra-denitis suppurativa symptoms, and these symptoms increased the hazard ratio of antidepressants (1.73, 95% confidence interval 1.17–2.56, p ≈ 0.006) and analgesics (hazard ratio 1.24, 95% confidence interval 1.11–1.39, p < 0.001). Pain and depression are the first comorbidities to present in hidradenitis suppura-tiva pathogenesis.

AB - Hidradenitis suppurativa is a common recurrent inflammatory skin disease. It is associated with multiple comorbidities whose temporal relationships are unknown due to long diagnostic delays. This study of otherwise healthy blood donors with self-reported symptoms of hidradenitis suppurativa investigated the temporal relationships of comorbidities. A prospective survival analysis on a nationwide cohort of blood donors, using registry data on drug prescription, was used to calculate the hazard ratio of time until first prescription of medical treatment for the following hidradenitis suppurativa-related comorbidities: heart disease, diabetes, depression, thyroid disease and pain. Hidradenitis suppurativa status was determined by a validated questionnaire, and the survival analysis was adjusted for age, sex, body mass index, smoking status and having an International Classification of Diseases Version 10 (ICD-10) diagnosis of hidradenitis suppurativa. Of the participants, 1,012 reported hidra-denitis suppurativa symptoms, and these symptoms increased the hazard ratio of antidepressants (1.73, 95% confidence interval 1.17–2.56, p ≈ 0.006) and analgesics (hazard ratio 1.24, 95% confidence interval 1.11–1.39, p < 0.001). Pain and depression are the first comorbidities to present in hidradenitis suppura-tiva pathogenesis.

KW - Analgesia

KW - Antidepressants

KW - Comorbidity

KW - Hidradenitis suppurativa

KW - Pre-scription

KW - Survival analysis

U2 - 10.2340/00015555-3737

DO - 10.2340/00015555-3737

M3 - Journal article

C2 - 33372684

AN - SCOPUS:85100280171

VL - 101

JO - Acta Dermato-Venereologica

JF - Acta Dermato-Venereologica

SN - 0001-5555

M1 - adv00376

ER -